-C Mccarthy Researcher Activity Profile

Research Author Detailed Information 

C Mccarthy Publication Rate By Year

C Mccarthy has published 7 paper(s) in 2007, 2 paper(s) in 2008, for a total of 9 research publications in total.

C C Mccarthy Author Information

LAST NAME: mccarthy

FIRST NAME: C

INITIALS: c

AFFILIATION:

Papers

C Mccarthy's Publication Record

1. Optimal Planning and Delivery of Radiotherapy for Oesophago-gastric Junction (OGJ) Cancers. Year Published: 2007
Academic Department of Radiation Oncology, Christie Hospital, Manchester, UK.
2. The length of lipids bound to human CD1d molecules modulates the affinity of NKT cell TCR and the threshold of NKT cell activation. Year Published: 2007
Tumour Immunology Unit, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, University of Oxford, Oxford, UK.
3. Immediate postoperative complications in DIEP versus free/muscle-sparing TRAM flaps. Year Published: 2007
Plastic and Reconstructive Service, Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA.
4. Comparison of measurements from photographed lateral cephalograms and scanned cephalograms. Year Published: 2007
Chesterfield Royal Hospital, Chesterfield, United Kingdom. mdp06jvc@sheffield.ac.uk
5. Immediate postoperative complications in DIEP versus free/muscle-sparing TRAM flaps. Year Published: 2007
Plastic and Reconstructive Service, Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA.
6. The length of lipids bound to human CD1d molecules modulates the affinity of NKT cell TCR and the threshold of NKT cell activation. Year Published: 2007
Tumour Immunology Unit, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, University of Oxford, Oxford, UK.
7. Comparison of measurements from photographed lateral cephalograms and scanned cephalograms. Year Published: 2007
Chesterfield Royal Hospital, Chesterfield, United Kingdom. mdp06jvc@sheffield.ac.uk
8. Efficacy and safety of rimonabant for improvement of multiple cardiometabolic risk factors in overweight/obese patients: pooled 1-year data from the Rimonabant in Obesity (RIO) program. Year Published: 2008
Department of Diabetology, Metabolism, and Clinical Nutrition, University Hospital Antwerp, Antwerp, Belgium. luc.van.gaal@uza.be
9. Efficacy and safety of rimonabant for improvement of multiple cardiometabolic risk factors in overweight/obese patients: pooled 1-year data from the Rimonabant in Obesity (RIO) program. Year Published: 2008
Department of Diabetology, Metabolism, and Clinical Nutrition, University Hospital Antwerp, Antwerp, Belgium. luc.van.gaal@uza.be